1. Home
  2. FSP vs SPRO Comparison

FSP vs SPRO Comparison

Compare FSP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.97

Market Cap

120.3M

Sector

Real Estate

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.30

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
SPRO
Founded
1981
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.3M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FSP
SPRO
Price
$0.97
$2.30
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
854.0K
473.5K
Earning Date
10-28-2025
11-13-2025
Dividend Yield
3.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$109,497,000.00
$40,549,000.00
Revenue This Year
$4.36
N/A
Revenue Next Year
$0.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.51
52 Week High
$2.21
$3.22

Technical Indicators

Market Signals
Indicator
FSP
SPRO
Relative Strength Index (RSI) 33.51 47.91
Support Level $1.39 $2.18
Resistance Level $1.04 $2.33
Average True Range (ATR) 0.06 0.11
MACD 0.02 -0.02
Stochastic Oscillator 47.05 30.77

Price Performance

Historical Comparison
FSP
SPRO

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: